LoadingLoadingLoadingNo insider open-market trades in 90 days (SEC Form 4). Congress: both buying and selling, $5K to $75K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
Citadel
$169.9M
added
Qube Research
$163.8M
bought
Sells/Trims (1)
Terry Smith
$458.4M
sold
Buys (3)
Damelio Frank A
$501K
bought
Bisaro Paul
$152K
bought
Mccallister Michael B
$233K
bought
Sells (1)
No tracked top-trader positions in ZTS as of Oct 21, 18:19 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Financial period
Q2 2026
Earnings per share
$1.85 expected
Revenue
$2.51B expected
Full Year 2026 guidance
$9.12B to $9.32B
No comparable estimate
Estimates as of Oct 21, 2026
EPS expected
$1.44 to $1.61
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $1.87 / $1.85Yahoo Finance | +0.95% in line | $2.47B $2.51B expected | -1.75% miss |
| Mar 31, 2026 | May 7, 2026 | $1.53 / $1.62Yahoo Finance | -5.28% miss | $2.26B No estimate | Unavailable |
| Dec 31, 2025 | Feb 12, 2026 | $1.48 / $1.40Yahoo Finance | +5.48% beat | $2.39B No estimate | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $1.70 / $1.62Yahoo Finance | +4.83% beat | $2.40B No estimate | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | $1.76 / $1.61Alpha Vantage | +9.32% beat | $2.46B No estimate | Unavailable |
| Mar 31, 2025 | May 6, 2025 | $1.48 / $1.40Alpha Vantage | +5.71% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 13, 2025 | $1.40 / $1.36Alpha Vantage | +2.94% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 4, 2024 | $1.58 / $1.46Alpha Vantage | +8.22% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.40B | $2.39B | $2.26B | $2.47B |
| Cost of what it sold | $715.0M | $743.0M | $641.0M | $673.0M |
| Gross profit | $1.69B | $1.64B | $1.62B | $1.79B |
| What it spent | ||||
| Research and development | $170.0M | $199.0M | $180.0M | $173.0M |
| Sales and admin | $579.0M | $619.0M | $588.0M | $592.0M |
| Other operating costs | — | — | $31.0M | $93.0M |
| Total operating expenses | $749.0M | $818.0M | $799.0M | $858.0M |
| What was left | ||||
| Operating profit | $936.0M | $826.0M | $822.0M | $937.0M |
| Interest on debt | $64.0M | $57.0M | $62.0M | $61.0M |
| Profit before tax | $887.0M | $761.0M | $758.0M | $866.0M |
| Tax | $166.0M | $158.0M | $157.0M | $175.0M |
| Net profit | $721.0M | $603.0M | $601.0M | $691.0M |
| EBITDA | $1.07B | $939.0M | $939.0M | $1.05B |
This stock is trending upward, and looks overbought after a fast run-up.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks
BearishOct 14Kabeer Aziz Acquires 2,465 Shares of AN2 Therapeutics at No Cost Under Director Compensation Plan
NeutralOct 13Why Did AllianceBernstein (NYSE:AB) Fall Despite Revenue Growth?
NeutralOct 13Reducing Zoetis' Fair Value Estimate in Face of Rising Competition; Wide Moat Remains Intact
Leans bearishOct 12Zoetis: Reducing Our Valuation to Reflect Greater Competitive Pressure, but Moat Remains Intact
Leans bearishOct 12Elanco Animal Health Reports Q2 2026 Results: Full Earnings Call Transcript
Leans bullishOct 8Neogen Shifts Focus to Scale Profitable Growth
NeutralOct 8Revenue rose 6.5% at Neogen (NEOG), alongside a swing to a quarterly loss.
Leans bullishOct 831 macro signals shaping ZTS right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
